Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

GeneDx Holdings (WGS) Current Assets (2020 - 2025)

GeneDx Holdings (WGS) has disclosed Current Assets for 6 consecutive years, with $268.3 million as the latest value for Q4 2025.

  • On a quarterly basis, Current Assets changed N/A to $268.3 million in Q4 2025 year-over-year; TTM through Dec 2025 was $268.3 million, a N/A change, with the full-year FY2025 number at $268.3 million, changed N/A from a year prior.
  • Current Assets was $268.3 million for Q4 2025 at GeneDx Holdings, up from $204.8 million in the prior quarter.
  • In the past five years, Current Assets ranged from a high of $538.5 million in Q3 2021 to a low of $99.0 million in Q2 2021.
  • A 5-year average of $262.2 million and a median of $213.3 million in 2023 define the central range for Current Assets.
  • Peak YoY movement for Current Assets: soared 36647.87% in 2021, then tumbled 56.03% in 2022.
  • GeneDx Holdings' Current Assets stood at $483.5 million in 2021, then tumbled by 56.03% to $212.6 million in 2022, then fell by 14.24% to $182.3 million in 2023, then decreased by 11.06% to $162.2 million in 2024, then skyrocketed by 65.44% to $268.3 million in 2025.
  • Per Business Quant, the three most recent readings for WGS's Current Assets are $268.3 million (Q4 2025), $204.8 million (Q2 2025), and $225.8 million (Q1 2025).